1005 GMT - Sanofi surprised with a sales beat of its skin and asthma drug Dupixent and a gross margin improvement given cost discipline, Stifel analysts say in a note. In addition, the French drugmaker's insulin portfolio is still benefiting from less competition in the U.S., where Danish obesity drug maker Novo Nordisk is prioritising its GLP-1 portfolio, they add. "[This was] a very good start to the year, offering upside to guidance, although Sanofi keeps it unchanged for the time being, which makes sense given uncertainties in the sector," they say. Shares fall 1% to 92.73 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 24, 2025 06:06 ET (10:06 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.